Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Life Sciences Tools & Services · CIK 0001717115
$63.81
-5.83% · live
Updated
$12.23B market value
From Tempus AI, Inc.'s FY2025 10-K, filed Feb 24, 2026 · read the filing
Tempus AI makes and sells software and computing services. It took in $1.27B last year, which makes it a mid-sized company. It spends more than it earns — losing about 19 cents on every dollar of sales.
The financial picture is led by growth, while profitability and debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score -1.60
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Tempus AI, Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Revenue
$693.4M → $1.27B
Operating income
-$691.1M → -$252.9M
Profit
-$705.8M → -$245.0M
Operating margin
-99.7% → -19.9%
Measured against FY2024, from the 10-K filed Feb 24, 2026
Improved: +83.4%
$693.4M to $1.27BCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote live), and what was published around it
TEM fell 5.83% on the latest quote. The average Technology company tracked here moved −1.27%, and the S&P 500 −1.04%. That is 4.6 points below its sector and 4.8 points below the market.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 27 analysts covering this company, as of . Their views, not this site's.
Of 27 analysts publishing on this company, 5 say strong buy, 9 say buy, 12 say hold and 1 say strong sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $245.0M last year, losing about 19 cents on every dollar of sales.
Yes, quickly. Sales grew 83.4% last year.
It is tight. For every $1 it owes, it owns $1.28 in assets. Its operating profit does not cover its interest bill — -3.60x against the interest it owes. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $245.0M and generated -$218.1M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 24, 2026Filing for FY2025 | FY202410-K · Feb 24, 2025Filing for FY2024 | FY202310-K · Feb 24, 2025Filing for FY2023 | FY202210-K · Feb 24, 2026Filing for FY2022 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|
| RevenueWhat is this? | $1.27B | $693.4M | $531.8M | $320.7M | +83.4% |
| Selling, general and administrative | $731.7M | $755.4M | $296.8M | $233.4M | −3.1% |
| Operating income | -$252.9M | -$691.1M | -$196.1M | -$265.4M | +63.4% |
| Operating marginOperating income ÷ revenueWhat is this? | -19.9% | -99.7% | -36.9% | -82.8% | +79.8 pts |
| Interest expense | $70.3M | $53.7M | $46.9M | $21.9M | +31.0% |
| Income before tax | -$291.1M | -$701.3M | -$213.5M | -$289.1M | +58.5% |
| Net income | -$245.0M | -$705.8M | -$214.1M | -$289.8M | +65.3% |
| Net marginNet income ÷ revenueWhat is this? | -19.3% | -101.8% | -40.3% | -90.4% | +82.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-1406.07 | $-5889.15 | $-3382.27 | $-4577.94 | +76.1% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| TEMTempus AI, Inc. · this page | 4.7/10 | 3/7 | 83.4% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 10,281 shares at $85.00 ($873.9K)
Holds 76,740 shares after this filing.
Sold on the open market
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +21.6% · Profit margin +15.1 pts · Profit turned positive — against Q2 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingWrite down why you are following Tempus AI, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 20 subsidiaries named in its 10-K, incorporated across 9 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from TEM's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 24, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 7 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 4.7 | 3/7 | 10-K, filed Feb 24, 2026 |
| FY2024 | 4.7 | 2/7 | 10-K, filed Feb 24, 2025 |
| FY2023 | 4.7 | 1/4 | 10-K, filed Feb 24, 2025 |
| FY2022 | 2.0 | 1/2 | 10-K, filed Feb 24, 2025 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
3 of 7 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. 2 could not be evaluated and are excluded from the total rather than counted as failures.
-1.60
In the distress zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: $438.2M narrower
-$691.1M to -$252.9MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: $460.8M narrower
-$705.8M to -$245.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +79.8 pts
-99.7% to -19.9%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +82.5 pts
-101.8% to -19.3%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: $4.5K narrower
-$5.9K to -$1.4KCritical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +77.4%
$341.0M to $604.8MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +45.4%
119849 to 174264Critical
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Changed: turned negative
$5.6M to $0.00Critical
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Deteriorated: $28.0M wider
-$211.2M to -$239.1MNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 30, 2026 — read it.
Improved: turned positive
-$42.8M to $5.6MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +15.1 pts
-13.6% to 1.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: turned positive
-$247.10 to $31.36Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +221.8%
$186.3M to $599.6MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +21.6%
$314.6M to $382.5MSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: $14.1M wider
-$61.8M to -$75.9MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: +3.8%
173381 to 179917Notable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 30, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: turned positive
-$125.9M to $5.6MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +37.6 pts
-36.2% to 1.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: turned positive
-$703.93 to $31.36Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +4.5 pts
-24.3% to -19.8%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +15.1%
$521.2M to $599.6MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +9.9%
$348.1M to $382.5MNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: $8.8M narrower
-$84.7M to -$75.9MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 14414.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
This company has not reported enough of the required figures to calculate this score.
| -19.3% |
| — |
| 3.63x |
| RVTYREVVITY, INC. | 6.0/10 | 6/8 | 3.7% | 8.4% | 73.25x | 0.68x |
|---|
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 2.0/10 | 4/8 | -0.9% | -3.6% | — | 1.24x |
|---|
| TECHBIO-TECHNE Corp | 8.0/10 | 8/9 | -0.4% | 15.0% | 62.33x | 0.23x |
|---|
| Median of peers | 6.0/10 | — | -0.4% | 8.4% | 67.79x | 0.68x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 8,595,389 shares after this filing.
Sold on the open market — 33,770 shares at $77.29 ($2.6M)
Holds 8,561,619 shares after this filing.
Sold on the open market — 16,152 shares at $78.23 ($1.3M)
Holds 8,545,467 shares after this filing.
Sold on the open market — 184 shares at $78.86 ($14.5K)
Holds 8,545,283 shares after this filing.
Sold on the open market — 17,359 shares at $76.57 ($1.3M)
Holds 14,968,110 shares after this filing.
Sold on the open market — 79,259 shares at $77.29 ($6.1M)
Holds 14,888,851 shares after this filing.
Sold on the open market — 37,950 shares at $78.23 ($3.0M)
Holds 14,850,901 shares after this filing.
Sold on the open market — 432 shares at $78.86 ($34.1K)
Holds 14,850,469 shares after this filing.
Sold on the open market — 965 shares at $76.57 ($73.9K)
Holds 808,666 shares after this filing.
Sold on the open market — 4,420 shares at $77.29 ($341.6K)
Holds 804,246 shares after this filing.
Sold on the open market — 2,091 shares at $78.23 ($163.6K)
Holds 802,155 shares after this filing.
Sold on the open market — 24 shares at $78.86 ($1.9K)
Holds 802,131 shares after this filing.
Sold on the open market — 6,431 shares at $76.57 ($492.4K)
Holds 143,569 shares after this filing.
Sold on the open market — 29,367 shares at $77.29 ($2.3M)
Holds 114,202 shares after this filing.
Sold on the open market — 14,042 shares at $78.23 ($1.1M)
Holds 100,160 shares after this filing.
Sold on the open market — 160 shares at $78.86 ($12.6K)
Holds 100,000 shares after this filing.
Sold on the open market — 700 shares at $70.00 ($49.0K)
Holds 15,874 shares after this filing.
Sold on the open market — 2,951 shares at $75.00 ($221.3K)
Holds 135,189 shares after this filing.
Sold on the open market — 7,062 shares at $75.00 ($529.6K)
Holds 60,804 shares after this filing.
Sold on the open market — 52,558 shares at $80.52 ($4.2M)
Holds 8,607,725 shares after this filing.
Sold on the open market — 4,942 shares at $81.09 ($400.7K)
Holds 8,602,783 shares after this filing.
Sold on the open market — 123,391 shares at $80.52 ($9.9M)
Holds 14,997,078 shares after this filing.
Sold on the open market — 11,609 shares at $81.09 ($941.4K)
Holds 14,985,469 shares after this filing.
Sold on the open market — 6,855 shares at $80.52 ($552.0K)
Holds 810,276 shares after this filing.
Sold on the open market — 645 shares at $81.09 ($52.3K)
Holds 809,631 shares after this filing.
Sold on the open market — 676 shares at $65.55 ($44.3K)
Holds 25,266 shares after this filing.
Sold on the open market — 13,046 shares at $62.12 ($810.4K)
Holds 34,374 shares after this filing.
Sold on the open market — 10,900 shares at $62.64 ($682.8K)
Holds 23,474 shares after this filing.
Sold on the open market — 5,900 shares at $63.80 ($376.4K)
Holds 17,574 shares after this filing.
Sold on the open market — 1,000 shares at $64.63 ($64.6K)
Holds 16,574 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 10,281 shares ($845.5K) on or after .
Shares originally obtained via Restricted Stock Units.
Filed notice to sell 250,000 shares ($19.5M) on or after .
Shares originally obtained via Stock Compensation.
Filed notice to sell 2,951 shares ($206.5K) on or after .
Shares originally obtained via Restricted Stock Units.
Filed notice to sell 9,311 shares ($651.5K) on or after .
Shares originally obtained via Restricted Stock Units.
Filed notice to sell 200,000 shares ($14.0M) on or after .
Shares originally obtained via Direct Investment.
Filed notice to sell 700 shares ($48.2K) on or after .
Shares originally obtained via Restricted Stock Awards.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Signed a material agreement
Made a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingSigned a material agreement · Terminated a material agreement · Took on a direct financial obligation · Sold shares outside a public offering · Reported another event
Read the filingQuarterly report for Q1 FY2026
Revenue +36.1% · Operating margin +2.5 pts · Profit $57.9M wider — against Q1 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +83.4% · Operating margin +79.8 pts · Operating income $438.2M narrower — against FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +84.7% · Operating margin +11.4 pts · Profit margin +18.0 pts — against Q3 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Revenue +89.6% · Operating margin +301.8 pts · Operating income $471.7M narrower — against Q2 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingSigned a material agreement · Took on a direct financial obligation · Sold shares outside a public offering · Reported another event
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2025
Revenue +75.4% · Operating margin +9.7 pts · Profit margin +17.8 pts — against Q1 FY2025
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-24. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Should You Be Worried About Tempus AI Stock?
Yahoo Finance ·
Here's How Tempus AI Demonstrates Improving Operating Leverage
Yahoo Finance ·
Tempus AI Stock Is The Expanded Drug Collaboration Material To The Bull Case
Yahoo Finance ·
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Yahoo Finance ·
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Yahoo Finance ·
Could You Have Seen The Run In Tempus AI Stock Coming?
Yahoo Finance ·
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Yahoo Finance ·
Fortune Unveils the "Fortune Future 120" 2026 List
Yahoo Finance ·
Tempus AI (TEM) Shares Just Moved, So What Is Going On?
Yahoo Finance ·
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Yahoo Finance ·
Tempus to Report Third Quarter 2026 Financial Results on November 2
Yahoo Finance ·
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Yahoo Finance ·
Primary sources and further research